AbbVie (NYSE:ABBV) Showcases Oncology Innovations Amidst 6% Share Price Dip
AbbVie (NYSE:ABBV) recently showcased significant advances in oncology, particularly with the introduction of new pipeline ...
2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income
AbbVie's shares dropped off a cliff in November after it announced a clinical setback for emraclidine, an investigational ...
Zacks.com on MSN15h
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...
Crain's Chicago Business2d
AbbVie accuses oncology partner of stealing trade secrets
Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...
AbbVie (NYSE:ABBV) Urges Shareholders To Reject Proposals On Voting Rules And Human Rights Due Diligence
AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of its May 2025 meeting, fostering investor attention. Despite reporting a Q4 ...